Staar Surgical Co (STAA)

NASD · Healthcare · Medical Instruments & Supplies · USA

Staar Surgical Co is a small cap company (market value between $300 million and $2 billion) in the Medical Instruments & Supplies industry.

STAAR Surgical designs, develops, manufactures, and sells implantable lenses for refractive eye surgery worldwide. The company's primary products are Implantable Collamer Lenses (ICLs), made from proprietary Collamer material, which treat myopia, hyperopia, astigmatism, and presbyopia. STAAR operates globally with direct and independent distribution channels across markets, generating nearly all revenue from ICL sales.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Staar Surgical Co stock.

Our verdict on STAA

Overvalued: intrinsic value $3.47 per share, market price $25.56, margin of safety -636.0% (as of 2026-11-17).

Its through-the-cycle earnings (0.1% median margin), capitalised at 10.5% with no growth, values the shares at $3.47; the price of $25.56 is 636% above that value.

ETFs with the most weight in STAA

17 more funds hold it; the full list is part of the paid plan.

More on STAA

Browse

Peers in Medical Instruments & Supplies

All 52 Medical Instruments & Supplies stocks

Cheaper than STAA in Medical Instruments & Supplies

21 more in this industry show a wider margin of safety.

Is STAA undervalued or overvalued?

STAA is overvalued (as of the 2026-11-17 close). Its through-the-cycle earnings (0.1% median margin), capitalised at 10.5% with no growth, values the shares at $3.47; the price of $25.56 is 636% above that value.

What is the intrinsic value of STAA?

$3.47 per share (as of the 2026-11-17 close), against a market price of $25.56. That is a margin of safety of -636.0%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.